What is the Sumitomo HM-10HC+ Medical Cyclotron?

The Sumitomo HM-10HC+ cyclotron is the only global 10 MeV device equipped with a solid-target new radionuclide system, producing ¹⁸F, ¹¹C, ¹³N, ⁶⁴Cu, ⁸⁹Zr, and ⁶⁸Ga radioactive nuclides. It represents the most advanced cyclotron technology, providing clinical support for prostate cancer, brain tumors, pediatric neuroblastoma, Alzheimer's disease, Parkinson's disease, breast cancer, gliomas, liver cancer, cardiovascular diseases, neuroendocrine tumors, lymphoma, non-Hodgkin lymphoma, and head-and-neck squamous cell carcinoma diagnosis and research.

Target Population for Sumitomo HM-10HC+

The HM-10HC+ cyclotron itself is not used directly for patient examination or therapy. Its applicable users are medical institutions (nuclear medicine departments) rather than individual patients. Its core function is to produce the radiotracers required on-site for PET-CT imaging. Therefore, the "target population" includes patients who require PET-CT scans to obtain radiotracers, specifically:

• Oncology patients: for diagnosis, staging, restaging, and efficacy evaluation of malignant tumors (using ¹⁸F and other radionuclides)

• Cardiovascular patients: for assessment of myocardial viability and cardiac function

• Neurological patients: for brain function evaluation and neurological disease diagnosis (using ¹¹C and other radionuclides)

• Health check-up population: for high-end tumor screening and early detection of potentials lesions

• Patients requiring radiotherapy planning support: providing precise localization information for biologically targeted radiotherapy

Core Features and Advantages

1. Wide range of radionuclides produced

Capable of producing multiple positron-emitting radionuclides such as ¹⁸F, ¹¹C, and ¹³N, meeting the labeling requirements of various PET-CT radiopharmaceuticals and expanding clinical diagnostic applications.

2. Self-shielding design

Equipped with a self-shielding system, reducing special radiation protection requirements for the installation room, lowering installation costs and spatial constraints, and facilitating hospital layout.

3. High yield and efficiency

Advanced ion source and target system design ensures high radionuclide production yield and stable output, satisfying the daily high-throughput imaging needs of the hospital.

4. Intelligent operation system

Integrated automated control and management software enables one-button start, automatic beam extraction and production, minimizing human operational errors and ensuring stable operation.

5. Compact structure

Compact device footprint, occupying minimal space, suitable for installation in nuclear medicine departments with limited space.

6. Mature and reliable technology

Sumitomo Heavy Industries' technology is mature, providing high stability and reliability, extensive global installations, comprehensive after-sales service, and rapid maintenance response.

7. GMP-compliant

Target materials and reagent delivery system are designed in accordance with Good Manufacturing Practice (GMP) standards, ensuring the purity and safety of produced radiopharmaceuticals.